Literature DB >> 6826629

Changes in crystal size and orientation of acidic glycosaminoglycans at the fracture site in fractured necks of femur.

G N Kent, R A Dodds, L Klenerman, R W Watts, L Bitensky, J Chayen.   

Abstract

The aim of this study was to try to elucidate the increased susceptibility of the neck of femur to fracture. Quantitative polarised light microscopy has been applied to fresh, undecalcified sections of samples of bone taken from the site of fracture, in specimens taken at operation from patients with fractures of the femoral neck or osteoarthritic femoral heads or from the equivalent site from otherwise normal subjects at necropsy. In all 21 specimens of fractured necks of femur, but in none of the other specimens, relatively large crystals (up to 2.5 X 0.5 micrometres) were found close to the site of fracture; the properties of these crystals were compatible with their being apatite. Measurement of the natural birefringence of the collagen showed no difference in the orientation of the collagen in all three types of specimen. However, the orientation of acidic glycosaminoglycans, measured by the birefringence of alcian blue bound to these moieties, was 45 per cent lower in the specimens from fractured necks of femur than in the other specimens, even though the total content of acidic glycosaminoglycans was unchanged. Although the decreased orientation was most marked close to the site of fracture, it was still apparent 15 millimetres from that site. These changes were unlikely to be simply the sequelae of fracture since they were not found in traumatic fractures of other bones. Thus it is conceivable that changes in the orientation of the ground substance allow formation of relatively large crystals of apatite and that such crystals, in the microcrystalline mass of apatite, are the cause of the increased fragility of such bones.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826629

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  9 in total

Review 1.  The pathogenesis and treatment of hip fractures.

Authors:  P Lips; K J Obrant
Journal:  Osteoporos Int       Date:  1991-09       Impact factor: 4.507

Review 2.  Osteoporosis: cause and management.

Authors:  R Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-07

Review 3.  Role of cortical bone in hip fracture.

Authors:  Jonathan Reeve
Journal:  Bonekey Rep       Date:  2017-01-13

Review 4.  Osteocyte death and hip fracture.

Authors:  C R Dunstan; N M Somers; R A Evans
Journal:  Calcif Tissue Int       Date:  1993       Impact factor: 4.333

5.  Bone architecture: collagen structure and calcium/phosphorus maps.

Authors:  Margaret Tzaphlidou
Journal:  J Biol Phys       Date:  2008-10-15       Impact factor: 1.365

6.  Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls.

Authors:  Samuel Gourion-Arsiquaud; Lyudmilla Lukashova; Jon Power; Nigel Loveridge; Jonathan Reeve; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

7.  Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture.

Authors:  Samuel Gourion-Arsiquaud; Dan Faibish; Elizabeth Myers; Lyudmila Spevak; Juliet Compston; Anthony Hodsman; Elizabeth Shane; Robert R Recker; Elizabeth R Boskey; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

8.  Time Related Changes of Mineral and Collagen and Their Roles in Cortical Bone Mechanics of Ovariectomized Rabbits.

Authors:  Xin-Xin Wen; Fa-Qi Wang; Chao Xu; Zi-Xiang Wu; Yang Zhang; Ya-Fei Feng; Ya-Bo Yan; Wei Lei
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 9.  The fragile elderly hip: mechanisms associated with age-related loss of strength and toughness.

Authors:  Jonathan Reeve; Nigel Loveridge
Journal:  Bone       Date:  2014-01-09       Impact factor: 4.398

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.